Quantcast

Latest Camptothecin Stories

2011-03-25 08:00:00

CAMBRIDGE, Mass., March 25, 2011 /PRNewswire/ -- Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US. The Phase 1b follows the successful completion of a...

2010-04-20 08:00:00

CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010. XMT-1001 is a conjugate of the anti-cancer molecule...

2009-11-12 06:00:00

CAMBRIDGE, Mass., Nov. 12 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today that a review of the Company's lead compound, XMT-1001, will appear in the November 12, 2009 special issue of Advanced Drug Delivery Reviews on Polymer Therapeutics: Clinical Applications and Challenges for Development. The review article, entitled, "XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer," was...

2009-09-01 07:24:01

Cell cycle checkpoints act like molecular tripwires for damaged cells. Leave the tripwire in place for too long, however, and cancer cells will press on regardless, making them resistant to certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies. "A lot of progress has been made in understanding the molecular details of checkpoint activation," senior author Tony Hunter, Ph.D., a professor in the Molecular and Cell Biology Laboratory was quoted as...

2008-12-22 05:00:00

BRIDGEWATER, N.J. and PARIS, Dec. 22 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Diatos S.A. today announced that they have entered into a global agreement to develop and commercialize DTS-108 for the treatment of solid tumors. DTS-108 is currently ready to begin Phase I clinical trials in Europe for the treatment of patients with advanced or metastatic solid tumors. Under the terms of the agreement, the license grants exclusive rights to Drais to develop and commercialize DTS-108...

2008-06-26 12:03:21

Taiwan Liposome and Aptuit Consulting, a subsidiary of Aptuit, has announced that Taiwan Liposome's Lipotecan cleared review by the FDA following the filing of an investigational new drug application, the first anticancer drug from Taiwan to achieve this milestone. Aptuit Consulting, Aptuit's global pharmaceutical drug development consultancy, managed the investigational new drug (IND)-enabling studies from manufacturing through IND submission and is engaged in the Phase I program. Taiwan...

2005-11-16 14:32:11

UC Davis Cancer Center researchers have discovered a genetic switch that causes cancer cells to become more sensitive to a drug administered to enhance radiation therapy effectiveness. The switch does not make the drug more toxic. The discovery may help scientists design new anti-cancer agents that enhance the effectiveness of radiation therapy with less toxicity than currently available radiosensitizing drugs. The finding is reported in the Priority Reports section of the last issue of the...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related